131 related articles for article (PubMed ID: 35847009)
1. Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Shi B; Ma W; Pan H; Shi Y; Zhang H; Xing S
Front Pharmacol; 2022; 13():860615. PubMed ID: 35847009
[No Abstract] [Full Text] [Related]
2. Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis.
Zhu Y; Liu K; Wang K; Peng L
Front Endocrinol (Lausanne); 2022; 13():909333. PubMed ID: 35909569
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma.
Liao W; Huang J; Hutton D; Zhu G; Wu Q; Wen F; Bai L; Li Q
Liver Int; 2019 Dec; 39(12):2408-2416. PubMed ID: 31544330
[TBL] [Abstract][Full Text] [Related]
4. Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US.
Chen J; Han M; Liu A; Shi B
Front Oncol; 2021; 11():734594. PubMed ID: 34778047
[TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer.
Chen HD; Zhou J; Wen F; Zhang PF; Zhou KX; Zheng HR; Yang Y; Li Q
J Cancer Res Clin Oncol; 2017 Feb; 143(2):361-368. PubMed ID: 27798730
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System.
Bai Y; Xu Y; Wu B
Gastroenterol Res Pract; 2017; 2017():2816737. PubMed ID: 29317864
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis.
Ji X; Liang W; Lv G; Ding C; Lai H; Li L; Zeng Q; Lv B; Sheng L
Front Pharmacol; 2022; 13():933648. PubMed ID: 36091770
[No Abstract] [Full Text] [Related]
12. Economic evaluation of intravenous alteplase for stroke with the time of onset between 4.5 and 9 hours.
Chen J; Liang X; Tong X; Han M; Ji L; Zhao S; Hu Z; Liu A
J Neurointerv Surg; 2023 Jan; 15(1):46-51. PubMed ID: 35074896
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Shi Y; Chen J; Shi B; Liu A
Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.
Li S; Li J; Peng L; Li Y; Wan X
Front Pharmacol; 2021; 12():736860. PubMed ID: 34966275
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
[TBL] [Abstract][Full Text] [Related]
16. Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness.
Li G; Xia YF; Huang YX; Okat D; Qiu B; Doyen J; Bondiau PY; Benezery K; Gao J; Qian CN
BMC Cancer; 2021 Aug; 21(1):944. PubMed ID: 34419008
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.
Liao W; Lei W; Feng M; Yang Y; Wu Q; Zhou K; Bai L; Wen F; Li Q
Adv Ther; 2021 Dec; 38(12):5662-5670. PubMed ID: 34664194
[TBL] [Abstract][Full Text] [Related]
18. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of mepolizumab for severe eosinophilic asthma in China.
Chaogang X; Mengna A; Zhen W; Ying L; Xin G; Xin Z; Shengjie Z; Yuan Z; Qian L; Wenbin M; Weiyi F
J Asthma; 2024 Mar; ():1-8. PubMed ID: 38470879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]